FABP4 and colorectal carcinoma: In a sensitivity complete case analysis including 1046 participants (76% of the total study sample), FABP‐4 was significantly associated with both CRC‐specific mortality (HR per SD = 1.10; 95% CI: 1.00–1.22; p = .05) and all‐cause mortality (HR per SD = 1.11; 95% CI: 1.02–1.21; p = .02) (Table S4).